TEAM-ACT will implement biology-based precision medicine for patients treated for metastatic colorectal cancer (CRC) at Oslo University Hospital (OUH) based on cutting-edge translational research. Drug screening of patient-derived organoid cultures will be combined with multi-level molecular analyses (genomics/transcriptomics/multiplex immunohistochemistry) of multiple tumor tissue samples from individual patients, and integrated into molecular prediction models by machine learning approaches. An immuno-oncology profiling program will be established, including immunophenotyping of tumors and immunotherapy testing in ex vivo co-cultures of malignant and tumor-infiltrating immune cells, to identify synergistic combination therapies with potential for "immune conversion", turning non-responsive tumors immunogenic.
PI: Ragnhild A. Lothe, co-PI Anita Sveen
Home page in Norwegian: